The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra, developed by South ...

SEOUL, Feb. 7 (Yonhap) -- Seoul shares fell marginally late Friday morning as investors took profit following three consecutive sessions of gains this week. The benchmark Korea Composite Stock Price ...

SEOUL, Feb. 7 (Yonhap) -- Seoul shares opened slightly lower Friday, as investors unloaded large caps after three consecutive sessions of gains this week. The benchmark Korea Composite Stock Price ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA.

Celltrion announced on Friday that its biosimilar Avtozma, a version of the autoimmune disease treatment Actemra (active ingredient tocilizumab), has received product approval from the US Food and ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

Stocks rose more than 1 percent Thursday driven by tech giant gains with the Trump administration's sweeping tariffs on pause ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...